PubMed Health⌕ Search

Biomedical subjects

D Ivanyi

Publications and source records attributed to D Ivanyi.

33 records · Page 2Linked to original sources
PubMed1990

Keratin subtypes in carcinomas of the uterine cervix: implications for histogenesis and differential diagnosis.

Normal epithelia and carcinomas of the human uterine cervix were studied by monoclonal antibodies chain specific for cytokeratins 4, 8, 10, 13, 14, 18, and 19. Most cells in 13 examined squamous carcinomas revealed a cytokeratin phenotype detected in ectocervical basal cells and endocervical subcolumnar reserve cells: 8+, 14+, 18+, 19+, 4-, 10-, 13-. We propose that these two cell types are closely related or identical and that squamous carcinoma of the cervix originates in this cell type. In more differentiated tumor cells cytokeratins 4, 10, and 13, which are present in suprabasal layers of the normal ectocervical epithelium, were coexpressed with basal cell cytokeratins. Thus, contrary to previous beliefs, all cytokeratins detected in carcinomas were also present in normal epithelium of uterine cervix. The cytokeratin profile of cervical adenocarcinomas corresponded to that of columnar endocervical cells (8+, 18+, 19+), although two of the three adenocarcinomas also expressed cytokeratin 4, which in the normal endocervix was detected in scattered single columnar cells only. The new monoclonal antibody DE-K14, specific for cytokeratin 14, proved a specific marker of subcolumnar reserve cells in the endocervix. It was also the only one that reacted with all cervical squamous carcinomas but with none of the cervical adenocarcinomas and, as such, has a potential value for pathological differential diagnosis of cervical tumors.

Adenocarcinoma↗
PubMed1989

New monoclonal antibodies recognizing epidermal differentiation-associated keratins in formalin-fixed, paraffin-embedded tissue. Keratin 10 expression in carcinoma of the vulva.

Two monoclonal antibodies (MAb) specific for differentiation-related epidermal keratins have been developed. They represent specific molecular probes for different stages of epidermal differentiation. Antibody DE-K10 is chain-specific for cytokeratin polypeptide no. 10 (56.5 kD) expressed in all suprabasal layers of the epidermis. Antibody DE-SCK is specific for modified stratum corneum keratins and thus represents a marker for the terminal step of epidermal differentiation. Since the epitopes identified by both antibodies are preserved in formalin-fixed, paraffin-embedded tissue sections, these antibodies can be used for retrospective studies of differentiation in various pathological processes. We have used antibody DE-K10 to study the cytokeratin 10 expression in 26 stage II or III vulvar squamous cell carcinomas. Preliminary data suggest an increased risk of recurrence in cytokeratin 10 negative tumours.

Antibodies, Monoclonal↗
PubMed1989

Absence of differentiation-related expression of keratin 10 in early stages of vulvar squamous carcinoma.

Using specific monoclonal antibodies (DE-K10 and DE-SCK respectively), the expression of some differentiation-related epidermal keratins was studied in 38 human vulvar squamous carcinomas. In the epidermis, expression of keratin 10 (K10) strictly paralleled the extent of differentiation; it was absent in the basal layer, appeared in the first suprabasal layers and increased in concentration towards the granular layer. However, K10 was rarely detected (1 case out of 12) in early stages of vulvar squamous carcinomas (tumours less than 2 cm, clinical stage I) regardless of the tumour grade. In larger and more advanced tumours (greater than 2 cm, clinical stages II and III), K10 was detected in 21 out of 26 cases. Its expression appeared to be related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts. Occasionally however, cells that did not show histological signs of keratinisation were also K10-positive. Modified stratum corneum keratins (recognized specifically by monoclonal antibody DE-SCK) were detected in the most keratinized areas (horn pearls and their close vicinity) of some K10-positive tumours, i.e., in a pattern close to their normal expression in terminally differentiated epidermal cells. These data suggest differences in the regulation of K10 expression during the differentiation processes in the normal keratinising squamous epithelium and in squamous carcinomas. While the normal pattern of vulvar epithelial differentiation is accompanied by an increasing expression of K10, malignant keratinocytes, also when these are histologically moderately or well differentiated, cease expressing this keratin in the early stages of tumour development.

Antibodies, Monoclonal↗
PubMed1987

Antigenic phenotype of NIH 3T3 cell line.

The antigenic phenotype of the NIH 3T3 cell line was examined by use of a panel of monoclonal antibodies and alloantisera specific for H-2 and several non-H-2 antigens. The binding of antibodies to cell surface antigens was examined by a complement-dependent microcytotoxicity test and indirect immunofluorescence quantitated by flow cytometry. The phenotype of the tested NIH 3T3 cell line was H-2q, Qa-2, Ly-6.2, Thy-1.2, Ly-23.2, and 9F 3+. The expression of H-2 antigens (Kq, Dq/Lq) was lower than that in the T-lymphocytes of the B10.Q (H-2q) strain, and the expression of Qa-2 was very low. From the Ly-6 complex, the antigen Ly-m6.2A was strongly expressed, while Ly-m.6B, Ly-m.6C, and antigens ThB and H9/25 were not detected. A monoclonal antibody specific for the nonpolymorphic antigen 9F 3 brightly stained 100% of NIH 3T3 cells. Inasmuch as the NIH 3T3 immortalized cell line was developed from outbred NIH Swiss mice, a syngeneic recipient for this cell line does not exist. However, on the basis of the determined antigenic phenotype the host most compatible to NIH 3T3 cells can be selected for in vivo experiments, where an immunocompetent recipient is required. Two inbred mouse strains identical with NIH 3T3 cells in the antigens examined in this study, B10.Q and DBA/1, are of potential use for transplantation with NIH 3T3 cells.

Animals↗
PubMed1986

Expression of Ly-6.2 and Thy-1 antigens on NIH 3T3 cells suppressed after transformation with activated human ras-oncogenes.

We have studied the expression of several cell surface antigens in NIH 3T3 cells after neoplastic transformation with activated human ras and myc oncogenes. The binding of monoclonal antibodies (MAbs), specific for mouse differentiation antigens Ly-6.2, Thy-1 and 9F3, to normal and transformed cells was assessed using a fluorescence-activated cell sorter (FACS IV). Significant reduction of Ly-6.2 and Thy-1 antigen expression was detected in cells transformed with either the N-ras, Ki-ras or H-ras oncogenes but not in c-myc transfected cells. 9F3 antigen expression remained at the original high level in all transfectants studied. Normal levels of Ly-6.2 and Thy-1 expression reappeared in revertants derived from unstable ras-transfectants. These data indicate that ras sequences did not preferentially transform cells that were deficient in Ly-6.2 and Thy-1 antigens. It was also shown that the reduced binding of anti-Ly-6.2 antibodies to ras-transfectants was not due to a masking effect of increased cell-surface sialylation occurring in ras-transfected cell lines. Other possible explanations of the detected phenotypic changes are discussed. The results extend the range of tumor-associated membrane alterations in NIH 3T3 cells following transfection with human tumor DNA containing activated ras oncogenes by a hitherto unreported alteration in the expression of Ly-6 and Thy-1 antigens.

Animals↗